Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Bock

Podiatrist Enumclaw, WA Doctor of Podiatric Medicine

NPI 1811125032 CMS profile 263957

1145 Cole St, Enumclaw, WA 98022

Open in the dashboard

General payments

$3,535

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Bock of Enumclaw, WA is reported in the CMS Open Payments database as having received $3,535 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $118 4
2023 General $1,517 9
2022 General $98 3
2021 General $700 9
2020 General $884 14
2019 General $189 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Bock
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Christopher Bock were reported at $28. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Christopher Bock Podiatrist median Middle half National median
2019 $189 $196 $72–$601 $163
2020 $884 $118 $38–$335 $114
2021 $700 $169 $57–$573 $132
2022 $98 $220 $74–$782 $149
2023 $1,517 $208 $71–$635 $160
2024 $118 $237 $87–$681 $164
2025 $28 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paragon 28, Inc. $1,864 9 payments
  2. Zimmer Biomet Holdings, Inc. $1,287 21 payments
  3. Next Science LLC $80 3 payments
  4. Horizon Therapeutics plc $71 4 payments
  5. Acell, Inc. $59 3 payments
  6. Nevro Corp. $40 2 payments
  7. Smith+Nephew, Inc. $38 1 payment
  8. Treace Medical Concepts, Inc. $33 2 payments
  9. Celularity, Inc. $32 2 payments
  10. Merck Sharp & Dohme Corporation $17 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,348 10 payments
  2. Food and Beverage $1,187 39 payments
Products named General payments · program years 2019–2025
  1. APEX 3D $1,470 6 payments
  2. Foot & Ankle-None $574 10 payments
  3. Product Portfolio $366 2 payments
  4. Sports Medicine-None $342 2 payments
  5. Trabecular Metal (TM) Ankle $128 1 payment
  6. Stratum Foot Plating System $66 1 payment
  7. EBI Bone Healing System $59 2 payments
  8. Xperience $56 1 payment
  9. BLASTX $56 1 payment
  10. SurgX $56 1 payment
  11. Other $475 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

222

Median for Podiatry: 160

Drug cost

$2,492

Median for Podiatry: $2,368

Branded share of claims

33.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 33 $966
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 40 $451
Diclofenac Sodium Generic 49 $308
Hydroxyzine Hcl Generic 15 $200
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 35 $194
Ibuprofen Generic 20 $157
Mupirocin Generic 15 $139
Tramadol Hcl Generic 15 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$719,929

Of which drugs: $557,315

Medicare patients

287

Average age 75

Services billed

3,768

166 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 55%
Diabetes 39%
Chronic kidney disease 26%
Atrial fibrillation 21%
Ischemic heart disease 20%
Heart failure 18%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 25 1,480 $156
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 12 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record